Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
Patient leaflets and SmPCs, drug interaction checker, official dosages and NHS pharmacy opening hours — all in one place.
The electronic medicines compendium (emc) no longer publishes a Summary of Product Characteristics for this product, which usually means it is no longer marketed in the UK. The patient leaflet below is kept for reference, but the product may not be available.
If you were prescribed this medicine, other products containing Adenosine may still be available. Do not stop your treatment — ask your pharmacist or GP what to use instead.
for The name of your medicine is Adenosine Infusion. The active ingredient in your medicine is adenosine. Adenosine belongs to a group of medicines called coronary vasodilators. This medicine is for diagnostic use only. Adenosine Infusion is given before a test called "myocardial perfusion imaging" to look at your heart. During this test you are given a medicine called a "radiopharmaceutical". Adenosine Infusion works by opening up your heart's blood vessels and allowing blood to flow more freely. This allows the" radiopharmaceutical" medicine to get into your heart. The doctor can see your heart and assess your heart condition. This is used if you are not capable of exercise or if an exercise stress test is not possible.
Patient Weight (kg) Infusion Rate (ml/min) 2.1 45-49 2.3 50-54 2.6 55-59 2.8 60-64 3.0 65-69 3.3 70-74 3.5 75-79 3.8 80-84 4.0 85-89 4.2 90-94 4.4 95-99 4.7 100-104 Paediatric population: The safety and efficacy of adenosine in children aged 0 to 18 years have not been established. Currently available data are described in section 5.1 (SmPC) but no recommendation on a posology can be made. Elderly: See dosage recommendations for adults. Pharmaceutical Particulars List of excipients Sodium chloride Water for injections Incompatibilities In the absence of compatibility studies, this medicinal product must not be mixed with other medicinal products. Shelf life Unopened: 36 months. The product should be used immediately after opening. Special precautions for storage Store below 25°C. Do not refrigerate. Nature and contents of container Clear, neutral type I glass vials (10ml) sealed with chlorobutyl rubber closures. Packs of 6 vials packed in a PVC tray in a cardboard carton. Special precautions for disposal Do not use if any particles or discolouration are noticed in the solution. Any unused product or waste material should be disposed of in accordance with local requirements Marketing Authorisation Holder Wockhardt UK Ltd, Ash Road North, Wrexham, LL13 9UF, UK Marketing Authorisation Number PL 29831/0456 Date of Revision of Text: 6/2023
105569/8
Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.
Customer
Wockhardt UK Limited
Colours Used
Description
Adenosine Infusion 3mg/ml
Black
Item Code
105569/8
Keyline (Non-Printing)
Profile
n/a
Technical Info (Non-Printing)
Size
148 x 460mm
Text Free Area (Non-Printing)
Min.Point Size
Other
Market
UK
Language
English
Standard 116
Barcode Proof By
CJE
Proof No.
1
Date
03/07/2023
Body Text Fonts:
Myriad Pro
Body Text Ctd.
Actual Min Point Size
8 pt
Cirrus_Info_Box
Very rare side effects (may affect up to 1 in 10,000 people)
If you are not sure why you are being given Adenosine Infusion or have any questions about how much Adenosine Infusion is being given to you, speak to your doctor or nurse. Adults (including the elderly)
Like all medicines, Adenosine Infusion can cause side effects, although not everybody gets them. While you are being given Adenosine Infusion you may have some of the following side effects: If any of the following side effects get worse, tell your doctor or nurse immediately and they will decide if you should continue the infusion or not. The side effects normally settle within seconds or minutes after the infusion is finished but you should tell your doctor or nurse if any of them happen. Very common (may affect more than 1 in 10 people)
6. Further information What Adenosine 30mg/10ml Solution for Infusion contains The active ingredient is adenosine. Each 10ml vial contains 30mg of adenosine (3mg/ml). The other ingredients are sodium chloride and water for injections. What Adenosine 30mg/10ml Solution for Infusion looks like and the contents of the pack Adenosine is a clear, colourless solution for infusion. Adenosine 30mg/10ml Solution for Infusion is available in packs of 6 single use glass vials. Marketing Authorisation Holder Wockhardt UK Ltd, Ash Road North, Wrexham LL13 9UF, UK Manufacturer CP Pharmaceuticals Ltd, Ash Road North, Wrexham LL13 9UF, UK Other formats: To listen to or request a copy of this leaflet in Braille, large print or audio please call, free of charge: 0800 198 5000 (UK only). Please be ready to give the following information: Product name Reference number Adenosine 30mg/10ml PL 29831/0456 Solution for Infusion This is a service provided by the Royal National Institute of Blind People. This leaflet was last revised in 06/2023
105569/8 ✂
Warning! We cannot accept responsibility for any errors in this proof after approval. Whilst we take extreme care at all times to ensure accuracy to our client's brief, the final responsibility must be taken by our client. IF YOU SIGN THIS PROOF YOU ARE SIGNIFYING FULL APPROVAL OF DESIGN AND TEXT.
Customer
Wockhardt UK Limited
Colours Used
Description
Adenosine Infusion 3mg/ml
Black
Item Code
105569/8
Keyline (Non-Printing)
Profile
n/a
Technical Info (Non-Printing)
Size
148 x 460mm
Text Free Area (Non-Printing)
Min.Point Size
Other
Market
UK
Language
English
Standard 116
Barcode Proof By
CJE
Proof No.
1
Date
03/07/2023
Body Text Fonts:
Myriad Pro
Body Text Ctd.
Actual Min Point Size
8 pt
Cirrus_Info_Box
Adenosine Infusion Keep out of the reach and sight of children. Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month. Store below 25°C. Do not refrigerate. The product should be used immediately after opening. Do not use if any particles or discolouration are noticed in the solution. Medicines should not be disposed of via wastewater or household waste. Your doctor or nurse will dispose of any unused medicine. These measures will help protect the environment.
Adenosine 30mg/10ml Solution for Infusion comes as infusion containing 30mg / 10ml. Always follow the dose your doctor or pharmacist has given you, and read the leaflet that comes with the medicine.
The active substance in Adenosine 30mg/10ml Solution for Infusion is adenosine.
Medicines with the same active substance, strength and form include: Adenosine 30 mg/10 ml solution for infusion, Adenosine 30mg/10ml Solution for Infusion. They are interchangeable only if your prescriber or pharmacist says so.
This leaflet reproduces the patient information leaflet approved for Adenosine 30mg/10ml Solution for Infusion, as published on the electronic medicines compendium (emc). The version printed inside your medicine’s packaging is the one that applies to you.
Whether a medicine is available over the counter or on prescription only depends on its licence. Check the leaflet, or ask your pharmacist — they can tell you straight away.
The text above reproduces the patient information leaflet approved for this medicine, restructured for easier reading.
Intravenous (IV) adenosine infusion is a coronary vasodilator for use in conjunction with radionuclide myocardial perfusion imaging in patients who cannot exercise adequately or for whom exercise is inappropriate.
Adenosine infusion is intended for use in hospitals with monitoring and cardio-respiratory resuscitation equipment available for immediate use if necessary.
It should be administered following the same procedure as for exercise testing where facilities for cardiac monitoring and cardio-respiratory resuscitation are available. During administration of adenosine infusion continuous ECG control is necessary as life-threatening arrhythmia might occur. Heart rate and blood pressure should be monitored every minute.
Posology:
Adults:
1. Adenosine Infusion should be administered undiluted as a continuous peripheral intravenous infusion at a dose of 140 µg/kg/min for six minutes using an infusion pump. Separate venous sites for Adenosine Infusion and radionuclide administration are recommended to avoid an adenosine bolus effect.
2. After three minutes of Adenosine Infusion, the radionuclide is injected to ensure sufficient time for peak coronary blood flow to occur. The optimal vasodilator protocol is achieved with six minutes of Adenosine Infusion.
3. To avoid an adenosine bolus effect, blood pressure should be measured in the arm opposite to the adenosine infusion.
The table below is given as a guide for adjustment of the infusion rate of undiluted adenosine infusion, in line with bodyweight (total dose 0.84 mg/kg).
Patient Weight (kg)
Infusion Rate (ml/min)
45-49
2.1
50-54
2.3
55-59
2.6
60-64
2.8
65-69
3.0
70-74
3.3
75-79
3.5
80-84
3.8
85-89
4.0
90-94
4.2
95-99
4.4
100-104
4.7
Paediatric population
The safety and efficacy of adenosine in children aged 0 to 18 years have not been established. Currently available data are described in section 5.1 but no recommendation on a posology can be made.
Elderly:
See dosage recommendations for adults.
Adenosine infusion is contraindicated in patients suffering from:
- Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
- Second or third degree atrioventricular (AV) block, sick sinus syndrome, except in patients with a functioning artificial pacemaker.
- Long QT syndrome.
- Severe hypotension.
- Unstable angina not successfully stabilised with medical therapy.
- Decompensated states of heart failure.
- Chronic obstructive lung disease with evidence of bronchospasm (e.g. asthma bronchiale).
- Concomitant use of dipyridamole (see section 4.5)
Adenosine is intended for use in a hospital setting with monitoring and cardio-respiratory resuscitation equipment available for immediate use if necessary. During administration, continuous ECG monitoring is necessary as life-threatening arrhythmia might occur. (section 4.2).
Because it has the potential to cause significant hypotension, adenosine infusion should be used with caution in patients with left main coronary stenosis, uncorrected hypovolemia, stenotic valvular heart disease, left to right shunt, pericarditis or pericardial effusion, autonomic dysfunction or stenotic carotid artery disease with cerebrovascular insufficiency. Adenosine infusion should be discontinued in any patient who develops persistent or symptomatic hypotension. There have been reports of cerebrovascular accident/transient ischemic attack, secondary to the haemodynamic effects of adenosine.
There have been reports of myocardial infarction shortly after use of Adenosine Infusion. Adenosine Infusion should be used with caution in patients with recent myocardial infarction, severe heart failure. Adenosine should be used with caution in patients with minor conduction defects (first degree A-V block, bundle branch block) that could be transiently aggravated during infusion.
Adenosine may trigger convulsions in patients who are susceptible to convulsions.
Adenosine should be used with caution in patients with atrial fibrillation or flutter and especially in those with an accessory by-pass tract since particularly the latter may develop increased conduction down the anomalous pathway.
Rare cases of severe bradycardia have been reported. Some occurred in early post-transplant patients; in the other cases occult sino-atrial disease was present. The occurrence of severe bradycardia should be taken as a warning of underlying disease and should lead to treatment discontinuation. Severe bradycardia would favour the occurrence of torsades de pointes, especially in patients with prolonged QT intervals. But to date, no case of torsades de pointes has been reported when adenosine is continuously infused.
The occurrence of respiratory failure (potentially fatal), asystole/cardiac arrest (potentially fatal), angina, severe bradycardia or severe hypotension should also lead to treatment discontinuation.
In patients with recent heart transplantation (less than 1 year) an increased sensitivity of the heart to adenosine has been observed.
Adenosine may precipitate or aggravate bronchospasm (see sections 4.3 and 4.8).
Adenosine infusion contains approximately 36mg sodium per vial (10ml). To be taken into consideration by patients on a controlled sodium diet.
Dipyridamole inhibits adenosine cellular uptake and metabolism, and potentiates the action of adenosine. In one study dipyridamole was shown to produce a 4 fold increase in adenosine actions. It is therefore suggested that adenosine infusion should not be administered to patients receiving dipyridamole; if use of adenosine infusion is essential, dipyridamole should be stopped 24 hours before hand, or the dose of adenosine should be greatly reduced.
Aminophylline, theophylline and other xanthines are competitive adenosine antagonists and should be avoided for 24 hours prior to use of Adenosine Infusion.
Food and drinks containing xanthines (tea, coffee, chocolate and cola) should be avoided for at least 12 hours prior to use of Adenosine Infusion.
Adenosine may interact with drugs tending to impair cardiac conduction.
Pregnancy:
There are no or limited amount of data from the use of adenosine in pregnant women. Animal studies are insufficient with respect to reproductive toxicity. Adenosine is not recommended during pregnancy unless the physician considers the benefits to outweigh the potential risks.
Breast-feeding
It is unknown whether adenosine metabolites are excreted in human milk.
Adenosine infusion should not be used during breast-feeding.
Not relevant.
Effects related to the known pharmacology of adenosine are frequent, but usually self-limiting and of short duration. Discontinuation of infusion may be necessary if the effect is intolerable.
Methylxanthines, such as IV aminophylline or theophylline have been used to terminate persistent side effects (50-125 mg by slow intravenous injection).
Adverse events are ranked under the heading of the frequency:
Very common (>1/10), Common (≥1/100, <1/10), Uncommon (≥1/1,000, <1/100), Rare (≥1/10,000, <1/1,000), Very rare (<1/10,000), Not known (cannot be estimated from available data).
Immune system disorders:
• Not known: anaphylactic reaction (including angioedema and skin reactions such as urticaria and rash).
Cardiac Disorders:
• Common: ST segment depression, sustained or non-sustained ventricular tachycardia, AV block (see section 4.4).
If sustained second or third degree AV block develops the infusion should be discontinued. If first degree AV block occurs, the patient should be observed carefully as a quarter of patients will progress to a higher degree of block.
• Uncommon: bradycardia sometimes severe (see section 4.4)
• Not known: asystole/cardiac arrest (sometimes fatal, especially in patients with underlying ischemic heart disease/cardiac disorders, see section 4.4): sinus tachycardia, atrial fibrillation, ventricular fibrillation, arteriospasm coronary which may lead to myocardial infarction.
Nervous system disorders
• Very common: headacheCommon: dizziness, light-headedness, paraesthesia
• Rare: tremor, drowsiness
• Not known: loss of consciousness / syncope, convulsions, especially in predisposed patients (see section 4.4)
Eye disorders
• Rare: blurred vision
Ear and labyrinth disorders:
• Rare: tinnitus
Respiratory, thoracic and mediastinal disorders:
• Very common: dyspnea (or the urge to breathe deeply)
• Rare: bronchospasm (see section 4.4), nasal congestion
• Very rare: respiratory failure (see section 4.4)
• Not known: apnea/respiratory arrest
Cases with fatal outcome of respiratory failure, of bronchospasm, and of apnea/respiratory arrest have been reported.
Gastro-intestinal disorders:
• Very common: abdominal discomfort
• Common: dry mouth
• Uncommon: metallic taste
• Not known: nausea, vomiting.
Renal and Urinary disorders:
• Rare: urinary urgency
Vascular disorders:
• Very common: flushing
• Common: hypotension, sometimes severe (see section 4.4)
General disorders and administration site conditions:
• Very common: chest pain or pressure, feeling of thoracic constriction/oppression
• Common: throat, neck and jaw discomfort
• Uncommon: sweating, discomfort in the leg, arm or back, feeling of general discomfort weakness/pain
• Very rare: injection site reactions
Reproductive system and breast disorders:
• Rare: nipple discomfort
Psychiatric disorders:
• Uncommon: nervousness
Reporting of suspected adverse reactions Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the Yellow Card Scheme at: www.mhra.gov.uk/yellowcard or search for MHRA
Yellow Card in the Google Play or Apple App Store.
Overdosage would cause severe hypotension, bradycardia or asystole. The half-life of adenosine in blood is very short, and side effects of adenosine infusion (when they occur) would quickly resolve when the infusion is discontinued. Administration of IV aminophylline or theophylline may be needed.
Ask anything about Adenosine 30mg/10ml Solution for Infusion. The assistant answers only from this leaflet — if the leaflet does not cover it, it will say so. It does not give medical advice.
Answers come from the patient leaflet published on the electronic medicines compendium (emc). They are not medical advice. Ask a pharmacist or your GP if you are unsure. For urgent help call NHS 111, or 999 in an emergency.
We use essential cookies to make the site work. We would also like to set optional cookies to understand how the site is used, so we can improve it. We will not set optional cookies unless you accept. See our cookie policy and privacy policy.